Results 161 to 170 of about 18,983,868 (378)
Stebbing: PHILOSOPHY AND THE PHYSICISTS/Poincaré: THE VALUE OF SCIENCE/Riezler: EINFÜHRUNG IN DIE KERNPHYSIK/MAGNETISM AND MAGNETIC MATERIALS/van der Ziel: FLUCTUATION PHENOMENA IN SEMI‐CONDUCTORS/Zinke und Brunswig: HOCHFREQUENZ‐MESSGERÄTE/Barrett: PROGRESS IN VACUUM SCIENCE AND TECHNOLOGY/Felici, Müller: ELEKTROSTATISCHE HOCHSPANNUNGS‐GENERATOREN UND IHRE INDUSTRIELLE ANWENDUNG/Vilbig: LEHRBUCH DER HOCHFREQUENZTECHNIK/Roth, Treu: PHYSIK OBERSTUFE [PDF]
Marise Ph. Born +9 more
openalex +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
In this explorative study, the abundance of circular RNA molecules in bone marrow stem cells was found to be elevated in patients with high‐risk myelodysplastic neoplasms, and to be associated with an increased risk of progression to acute myeloid leukemia.
Eileen Wedge +17 more
wiley +1 more source
Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon +4 more
wiley +1 more source
The APS upgrade offering new opportunities for materials science [PDF]
Uta Ruett
openalex +1 more source

